Article
Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea.
Haematologica - 1 Jul 2022
Allard Pierre, Alhaj Nareen, Lobitz Stephan, Cario Holger, Jarisch Andreas, Grosse Regine, Oevermann Lena, Hakimeh Dani, Tagliaferri Laura, Kohne Elisabeth, Kopp-Schneider Annette, Kulozik Andreas E, Kunz Joachim B
Abstract excerpt
The course of sickle cell disease (SCD) is modified by polymorphisms boosting fetal hemoglobin (HbF) synthesis. However, it has remained an open question how these polymorphisms affect patients who are treated with the HbF-inducing drug hydroxyurea/ hydroxycarbamide. The German SCD registry offers the opportunity to answer this question, because >90% of patients are treated according to national guidelines...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.